PNMA6A and acute myeloid leukemia: Interestingly, peripheral blood (PB) taken 2 months after the transplantation revealed that 14 out of 17 recipients of MA6/WT presented with AML cells (CD45.2+ CD11b+) higher than 20 % of all nucleated cells, as compared to only 5 out of 17 MA6/KO recipients.